Esperion Therapeutics ESPR 深 滬
已收盤 08-29 16:00:00 美东时间
2.22
+0.010
+0.45%
華盛通- 最 高2.28
- 今 開2.22
- 成交量 818.87万股
- 最 低 2.09
- 昨 收 2.21
- 總市值 4.40亿
- 52周最高 3.94
- 市盈率 靜 --
- 換手率 4.14%
- 52周最低 0.6925
- 委 比 -35.01%
- 總股本 1.98亿
- 歷史最高 120.96
- 量 比 1.88
- 振 幅 8.60%
- 歷史最低 0.6925
- 每 手 1
- 風險率 0.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
<p>Esperion welcomed the inclusion of bempedoic acid as the only non-statin therapy newly recommended for LDL-C lowering and cardiovascular risk reduction in the 2025 ESC/EAS guidelines. The guidelines highlight the use of non-statin therapies, particularly bempedoic acid, for patients unable to take statins, and recommend its addition to maximally tolerated statin therapy for high-risk patients. Esperion noted the guidelines affirm their strateg...
08-29 12:00
Esperion to Participate in Upcoming September Investor Conferences
Esperion Therapeutics will participate in two webcasted investor events in September 2025: the Cantor Global Healthcare Conference on September 3 and the H.C. Wainwright Global Investment Conference on September 8. Both events will be live-streamed on Esperion's investor website, with replays available for approximately 90 days. Esperion is a commercial-stage biopharmaceutical company focused on developing novel, non-statin lipid-lowering therapi...
08-26 12:00
Esperion Delays Q2 2025 Financial Report Filing
Esperion ( ($ESPR) ) has released a notification of late filing. Esperion Thera...
08-12 06:08
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion granted 12 new employees 73,500 restricted stock units (RSUs) under its 2017 Inducement Equity Incentive Plan on August 5, 2025. The RSUs vest over four years, with 25% vesting after one year and the remaining 75% vesting quarterly over the next three years, contingent on continued employment. Esperion Therapeutics is a biopharmaceutical company developing innovative treatments for cardiovascular diseases, including once-daily non-statin...
08-07 21:30
Esperion rises after revenue beat, Q1 profitability expectation
Esperion Therapeutics (NASDAQ:ESPR) shares rose on Tuesday after the company reported second quarter revenue above estimates, and now expects to achieve sustainable profitability beginning in the firs...
08-05 23:53
Esperion Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
Esperion Therapeutics shares are trading higher after the company reported bett...
08-05 20:51
Esperion Therapeutics Q2 EPS $(0.02) Beats $(0.14) Estimate, Sales $82.385M Beat $63.142M Estimate
Esperion Therapeutics (NASDAQ:ESPR) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.14) by 85.51 percent. This is a 93.94 percent increase over losses of $(0.33) per share
08-05 18:01
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update
Esperion Therapeutics reported Q2 2025 financial results, highlighting a 12% year-over-year increase in total revenue to $82.4 million, with U.S. product revenue growing 42% to $40.3 million. The company reached settlement agreements with three ANDA filers, delaying generic versions of NEXLETOL until 2040. Operating income from ongoing operations was achieved for the first time, signaling potential sustainable profitability starting Q1 2026. Glob...
08-05 10:00
What to Expect from Esperion Therapeutics's Earnings
Esperion Therapeutics (NASDAQ:ESPR) is gearing up to announce its quarterly ear...
08-05 05:02
